<DOC>
	<DOCNO>NCT01061060</DOCNO>
	<brief_summary>This study attempt examine effect oral prostaglandin I2 ( Beraprost Na ) , administer eight week , endothelial cell functional disorder among asymptomatic high risk diabetes mellitus patient .</brief_summary>
	<brief_title>The Effect Prostaglandin I2 Endothelial Cell Function Disorder Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description>This study plan include subject complaint peripheral microvascular symptom evidence neither coronary arterial disease peripheral arterial disease show normal finding vascular stiffness test ( PWV ABI ) ) plethysmography leg ( PVR ) ) , among Type II diabetes mellitus patient forty-five ( 45 ) year old old , This study conduct use randomize double blind method . These drug distribute pharmacy clinical study center administer randomly eight week study allots patient use double blind method . Beraprost Na administer along placebo manufacture manufacturer identical exterior look weight Beraprost Na . After eight week drug administration , investigation attempt verify symptomatic improvement change endothelial function use VENDYSÂ® ICG perfusion imaging .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>Type II diabetes mellitus patient Patients symptoms minute peripheral blood flow disorder Cases either alreadydiagnosed coronary arterial disease peripheral vascular disease Cases history stroke Cases abnormal find vascular stiffness test ( PWV ABI ) plethysmography leg ( PVR ) Pregnant woman fertile woman unclear pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Prostaglandin I2</keyword>
	<keyword>Beraprost Na</keyword>
	<keyword>Endothelial cell function</keyword>
</DOC>